We have reported a case of autosomal recessive juvenile parkinsonism PARK6 with a 30-year history. She developed tremor of right lower limb at the age of 23. At the age of 28, she received a clinical diagnosis of early-onset Parkinson's disease. She showed clinical improvements by the treatment with trihexyphenidyl, but symptoms showed slow progression over the subsequent years. L-DOPA therapy was introduced at the age of 42, and five years later, L-DOPA-induced dyskinesia developed. Dystonia, diurnal fluctuation and sleep benefit were absent. She carried a homozygous missense mutation in PINK1 gene, and was diagnosed as PARK6. The brain MRI did not show apparent abnormality. 18F-FDG-positron emission topography (PET) displayed normal uptake in the brain, suggesting normal glucose metabolism. PET imaging with a dopamine D2 receptor ligand 11C-raclopride revealed that postsynaptic 11C-raclopride uptake was normal in the bilateral putamen. After the introduction of pramipexisol, she showed clinical improvements. L-DOPA-induced dyskinesia disappeared with the gradual tapering and withdrawal of L-DOPA. In this PARK6 case, postsynaptic D2 receptors of the nigro-striatal dopaminergic neurons were thought to be maintained despite a long disease history.
[1]
H. Fukuyama,et al.
Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT
,
2007,
Journal of the Neurological Sciences.
[2]
Nobutaka Hattori,et al.
Novel PINK1 mutations in early‐onset parkinsonism
,
2004,
Annals of neurology.
[3]
Nicola Pavese,et al.
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
,
2004,
Brain : a journal of neurology.
[4]
R. Nussbaum,et al.
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
,
2004,
Science.
[5]
Paola Piccini,et al.
Clinical and subclinical dopaminergic dysfunction in PARK6‐linked parkinsonism: An 18F‐dopa PET study
,
2002,
Annals of neurology.